JP Morgan Chase
FOMX

JP Morgan Chase’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

JP Morgan Chase’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-112,536
Closed -$270K – 6094
2019
Q2 		$270K Buy
112,536
+22,027
+24% +$65.8K ﹤0.01% 4542
2019
Q1 		$339K Buy
+90,509
New +$339K ﹤0.01% 4392
2018
Q3 		– Sell
-60,488
Closed -$303K – 5926
2018
Q2 		$303K Buy
+60,488
New +$311K ﹤0.01% 4391
2017
Q4 		– Sell
-217
Closed -$1K – 5671
2017
Q3 		$1K Sell
217
-11,589
-98% -$59.9K ﹤0.01% 4928
2017
Q2 		$55K Buy
+11,806
New +$52.7K ﹤0.01% 4330
2017
Q1 		– Sell
-611
Closed -$7K – 5331
2016
Q4 		$7K Buy
+611
New +$5.75K ﹤0.01% 4845
2016
Q2 		– Sell
-188,925
Closed -$1.23M – 5084
2016
Q1 		$1.23M Sell
188,925
-17,075
-8% -$110K ﹤0.01% 2969
2015
Q4 		$1.67M Buy
+206,000
New +$1.54M ﹤0.01% 2850
2015
Q1 		– Sell
-732,890
Closed -$5.14M – 4366
2014
Q4 		$5.14M Buy
732,890
+132,890
+22% +$760K ﹤0.01% 2389
2014
Q3 		$3.27M Buy
+600,000
New +$3.44M ﹤0.01% 2625

Other funds holding FOMX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase's FOMX Position: Q3 2019 in Review

JP Morgan Chase sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q3 2019, closing a stake of 112,536 shares — an estimated $270K sold.

JP Morgan Chase first reported a position in FOMX in Q3 2014 and held it in 10 quarters. The position peaked at $5.14M in Q4 2014. 59 funds tracked by Wall St. Rank hold FOMX as of Q3 2019.

  • JP Morgan Chase reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q3 2019 after selling out during the quarter.
  • JP Morgan Chase sold 112,536 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q3 2019, an estimated $270K.
  • JP Morgan Chase first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q3 2014 and held it in 10 quarters.
  • JP Morgan Chase's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $5.14M in Q4 2014.
  • 59 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q3 2019.

Based on JP Morgan Chase's 13F filing for Q3 2019, filed 12 Nov 2019.